New weekly shot challenges leading Weight-Loss drug in major trial
NCT ID NCT06604624
First seen Apr 08, 2026 · Last updated Apr 18, 2026 · Updated 4 times
Summary
This study tested a new weekly injection called HD1916 against an established drug, semaglutide, to see which is better for weight loss in adults with obesity who do not have diabetes. Over 460 participants received one of the two injections for 44 weeks while researchers tracked changes in their weight and safety. The goal was to see if the new drug works as well or better for controlling weight over nearly a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
Conditions
Explore the condition pages connected to this study.